LENZ Therapeutics, Inc. (NASDAQ:LENZ – Get Free Report) has been assigned an average recommendation of “Buy” from the seven research firms that are currently covering the company, Marketbeat.com reports. Six investment analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 12-month target price among brokerages that have issued ratings on the stock in the last year is $35.40.
A number of equities research analysts have recently commented on LENZ shares. HC Wainwright began coverage on shares of LENZ Therapeutics in a research report on Monday, August 12th. They issued a “buy” rating and a $38.00 target price for the company. Piper Sandler reissued an “overweight” rating and issued a $36.00 target price on shares of LENZ Therapeutics in a research note on Thursday, August 15th. William Blair upgraded LENZ Therapeutics to a “strong-buy” rating in a report on Friday, August 30th. Finally, Raymond James assumed coverage on LENZ Therapeutics in a report on Friday, September 27th. They issued an “outperform” rating and a $37.00 price target for the company.
Read Our Latest Stock Analysis on LENZ
Institutional Trading of LENZ Therapeutics
LENZ Therapeutics Price Performance
LENZ opened at $23.98 on Tuesday. LENZ Therapeutics has a twelve month low of $14.07 and a twelve month high of $29.82. The stock’s 50-day moving average is $22.92.
LENZ Therapeutics (NASDAQ:LENZ – Get Free Report) last announced its earnings results on Wednesday, August 14th. The company reported ($0.40) EPS for the quarter, beating analysts’ consensus estimates of ($0.49) by $0.09. On average, sell-side analysts expect that LENZ Therapeutics will post -2.81 earnings per share for the current fiscal year.
About LENZ Therapeutics
LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.
Further Reading
- Five stocks we like better than LENZ Therapeutics
- What is a Low P/E Ratio and What Does it Tell Investors?
- Ciena Stock Powers the AI Cloud Boom—Don’t Miss Out
- Dividend King Proctor & Gamble Is A Buy On Post-Earnings Weakness
- Affirm’s Path to Profitability Elevates with Interest Rate Cuts
- 3 Small Caps With Big Return Potential
- RPM International Thrives in Rate-Cut Driven Construction Rally
Receive News & Ratings for LENZ Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LENZ Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.